Glenmark Plays Down Napo’s Deal Termination For Crofelemer; Expects Launch In 12-18 Months
This article was originally published in PharmAsia News
Executive Summary
India’s Glenmark will go ahead with filing crofelemer NDA despite conflict with its partner Napo Pharmaceuticals, which cancelled the development partnership